GALE 302

Drug Profile

GALE 302

Alternative Names: E39'; Folate binding protein J65 - Galena Biopharma; J65

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Galena Biopharma
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer

Most Recent Events

  • 14 Nov 2016 Analysis of post-booster immunogenicity data from a phase Ib trial in Ovarian cancer and Breast cancer released by Galena Biopharma
  • 20 Oct 2016 Immunogenicity data from a phase Ib trial in Breast cancer and Ovarian cancer released by Galena Biopharm
  • 10 Jun 2016 GALE 302 receives Orphan Drug status for Ovarian cancer (Prevention of relapse, Combination therapy, Adjuvant therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top